@article{JTD4106,
author = {Zhen-Kui Pan and Feng Ye and Xuan Wu and Han-Xiang An and Jing-Xun Wu},
title = {Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {3},
year = {2015},
keywords = {},
abstract = {Objective: Programmed cell death 1 (PD-1) and one of its ligands, PD-L1, are key immune checkpoint proteins. Evidences showed PD-L1 is an emerging biomarker for immunotherapy by anti-PD-1 and anti- PD-L1 antibody in non-small cell lung cancer (NSCLC). To investigate the association of PD-L1 protein expression with clinicopathological features and its impact on survival outcome, we conducted a metaanalysis.
Methods: A comprehensive literature search of electronic databases (up to July 10, 2014) was performed. Correlation between PD-L1 expression and clinicopathological features and overall survival (OS) was analyzed by synthesizing the qualified data. Publication biases were examined.
Results: A total of 1,550 NSCLC patients from 9 studies were included. The pooled odds ratios (ORs) indicated high PD-L1 expression was associated with poor tumor differentiation [OR =0.53, 95% confidence interval (CI): 0.39-0.72, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/4106}
}